U.S. FDA warns on Daiichi Sankyo blood pressure drugs
July 3 (Reuters) - U.S. health regulators warned on Wednesday that Daiichi Sankyo Inc's blood pressure drugs Benicar, Benicar HCT, Azor and Tribenzor can cause severe, chronic diarrhea and substantial weight loss, sometimes requiring hospitalization.
The Food and Drug Administration said the intestinal problems, known as sprue-like enteropathy, can develop months to years after starting on the drug, which is known generically as olmesartan medoxomil.
The drug is one of a class of drugs known as angiotensin II receptor blockers, or ARBs. The agency said sprue-like enteropathy has not been detected with other ARB drugs.
- Hong Kong protesters stockpile supplies, fear fresh police advance |
- Kurds seize Iraq/Syria border post; Sunni tribe joins fight against Islamic State |
- Protesters stay out on Hong Kong streets, defying Beijing |
- Special Report: Islamic State uses grain to tighten grip in Iraq
- EBay follows Icahn's advice, plans PayPal spinoff in 2015 |